Particle.news
Download on the App Store
55 ARTICLES
·
2w ago

Novo Nordisk Cuts Growth Forecast with GLP-1 Competition Intensifying

New oral GLP-1 rivals alongside rising lawsuit counts have prompted Novo Nordisk to lower its full-year outlook on the eve of a leadership change.

Image
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. REUTERS/Mike Blake/File Photo
A view shows a Novo Nordisk sign outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. REUTERS/Tom Little/ File Photo
Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss, are seen in a fridge at a health clinic in Hyderabad, India, April 14, 2025. REUTERS/Almaas Masood/ File Photo

Overview

  • Novo Nordisk’s GLP-1 segment sales grew 16% in H1 2025 to DKK 155 billion with Ozempic up 8% and Wegovy up 56%, but growth lagged last year’s gains.
  • The company trimmed its 2025 full-year sales growth forecast to 8–14% from 13–21% after reporting slower-than-expected performance.
  • Novo Nordisk filed 14 new lawsuits against compounding pharmacies this quarter, bringing its total legal actions over unapproved generics to 132.
  • Outgoing CEO Lars Fruergaard Jørgensen warned that layoffs may be necessary as incoming chief executive Maziar Mike Doustdar takes the helm today.
  • Eli Lilly’s experimental GLP-1 pill orforglipron delivered 12.4% average weight loss in a late-stage trial—below Wegovy’s benchmark—triggering double-digit swings in both companies’ share prices.